Group 1 - The core point of the news is that Aomei Medical's stock price dropped by 5% to 12.16 yuan per share, with a trading volume of 193 million yuan and a turnover rate of 3.47%, resulting in a total market capitalization of 7.701 billion yuan [1] - Aomei Medical, established on July 24, 2002, and listed on March 11, 2019, specializes in the research, production, and sales of disposable medical consumables, particularly medical dressings [1] - The main revenue composition of Aomei Medical includes surgical and wound care at 79.19%, other categories at 6.62%, infection protection at 5.05%, advanced dressings at 4.68%, and hygiene care at 4.46% [1] Group 2 - Among the top ten circulating shareholders of Aomei Medical, a fund under Yongying Fund is included, and the Medical Device ETF (159883) entered the top ten shareholders in the third quarter, holding 1.5656 million shares, which accounts for 0.35% of the circulating shares [2] - The Medical Device ETF (159883) was established on April 22, 2021, with a latest scale of 3.677 billion yuan, and has achieved a year-to-date return of 8.42%, ranking 1994 out of 5549 in its category [2] - The fund has a one-year return of 14.06%, ranking 3672 out of 4285, and has experienced a cumulative loss of 47.1% since its inception [2] Group 3 - The fund manager of the Medical Device ETF (159883) is Shu Kefa, who has been in the position for 2 years and 169 days, managing a total fund size of 5.205 billion yuan [3] - During the tenure of the fund manager, the best fund return was 103.17%, while the worst return was -30.27% [3]

Core Viewpoint - Aomei Medical announced the completion of its share repurchase plan, indicating a strategic move to enhance shareholder value and potentially stabilize stock prices [2] Group 1: Share Repurchase Details - The company initiated a share repurchase program on March 25, 2025, using a dedicated repurchase account through centralized bidding [2] - As of the announcement date, Aomei Medical has repurchased a total of 5,306,200 shares, which represents 0.8379% of the company's total share capital [2]

Group 1 - The company, Aomei Medical (002950.SZ), announced that it has repurchased a total of 5.3062 million shares through the Shenzhen Stock Exchange, accounting for 0.8379% of its total share capital [1] - The highest transaction price during the repurchase was 10.05 yuan per share, while the lowest was 8.33 yuan per share [1] - The total amount paid for the repurchased shares was 50,618,607.00 yuan, excluding transaction fees such as stamp duty and commissions [1] Group 2 - The repurchase amount has exceeded the lower limit of the total funds allocated for the repurchase plan [1] - The repurchase complies with relevant laws and regulations and aligns with the company's share repurchase scheme [1] - The implementation of this repurchase has been completed [1]

证券代码：002950 证券简称：奥美医疗 公告编号：2026-002 奥美医疗用品股份有限公司 二、回购股份实施情况与回购股份方案不存在差异的说明 本次股份回购的资金来源、使用资金总额、回购价格、回购方式以及回购实施期 限等均符合公司董事会审议通过的回购方案，实际执行情况与原披露的回购方案不存 在差异，公司回购金额已超过回购方案中的回购资金总额下限，且未超过回购资金总 额上限。本次股份回购的实施符合相关法律、法规、规范性文件及公司股份回购方案 的规定。 关于股份回购实施结果暨股份变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 奥美医疗用品股份有限公司（以下简称"公司"）董事会于 2025 年 1 月 20 日召 开第三届董事会第十二次会议，审议通过了《关于以集中竞价交易方式回购公司股份 方案的议案》，同意公司以自有资金及股票回购专项贷款资金通过集中竞价交易方式回 购公司股份，用于股权激励或员工持股计划。本次回购价格不超过人民币 11.00 元/股 （含），回购股份的资金总额不低于人民币 5,000 万元（含）且不超过人民币 10,000 万元（含 ...

Group 1 - The commercial aerospace sector has seen multiple stocks with consecutive trading limits, with Galaxy Electronics achieving 5 consecutive limits and Jiangshun Technology achieving 4 consecutive limits [1][2] - A total of 113 stocks in the A-share market reached their daily limit on January 9, with the robotics sector's Fenglong Co. leading with 11 consecutive limits [1] - Other notable stocks include ST Dongyi with 7 consecutive limits in computing power, ST Chengchang with 6 in aerospace and military industry, and ST Yatai with 5 in chemicals [1] Group 2 - Additional stocks in the commercial aerospace sector include Aerospace Electronics, which has 2 consecutive limits, and Qian Zhao Optoelectronics, also with 2 consecutive limits [2] - The robotics sector continues to show strength with stocks like ST Dehao and Pailin, both achieving 2 consecutive limits [2] - The industrial internet sector is represented by Hangxiao Steel Structure, which has also reached 2 consecutive limits [2]

Company Overview - Aomei Medical is located in Zhijiang, Hubei Province, and was established on July 24, 2002. The company went public on March 11, 2019. Its main business involves the research, production, and sales of disposable medical consumables, including medical dressings [1]. - The revenue composition of Aomei Medical includes: surgical and wound care (79.19%), other categories (6.62%), infection protection (5.05%), advanced dressings (4.68%), and hygiene care (4.46%) [1]. Financial Performance - As of September 30, 2025, Aomei Medical achieved a revenue of 2.597 billion yuan, representing a year-on-year growth of 5.98%. The net profit attributable to the parent company was 349 million yuan, reflecting a year-on-year increase of 31.54% [2]. - Since its A-share listing, Aomei Medical has distributed a total of 1.099 billion yuan in dividends, with 91.913 million yuan distributed over the past three years [3]. Stock Performance - On January 8, Aomei Medical's stock price increased by 2.32%, reaching 11.46 yuan per share, with a trading volume of 50.793 million yuan and a turnover rate of 1.00%. The total market capitalization is 7.257 billion yuan [1]. - Year-to-date, Aomei Medical's stock has risen by 4.95%, with a 5-day increase of 5.04%, a 20-day increase of 0.79%, and a 60-day increase of 18.76% [1]. Shareholder Information - As of September 30, 2025, Aomei Medical had 37,800 shareholders, an increase of 0.71% from the previous period. The average number of circulating shares per person decreased by 0.71% to 11,965 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fifth largest, holding 17.9166 million shares, an increase of 5.5221 million shares from the previous period. The Medical Device ETF (159883) is the tenth largest shareholder, holding 1.5656 million shares as a new shareholder [3].

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 奥美医疗用品股份有限公司（以下简称"公司"）董事会于 2025 年 1 月 20 日召开第 三届董事会第十二次会议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议 案》，同意公司以自有资金及股票回购专项贷款资金通过集中竞价交易方式回购公司股份， 用于股权激励或员工持股计划。本次回购价格不超过人民币 11.00 元/股（含），回购股份 的资金总额不低于人民币 5,000 万元（含）且不超过人民币 10,000 万元（含），具体回购 资金总额以实际使用的资金总额为准。回购股份的实施期限为自公司董事会审议通过本次 回购方案之日起 12 个月内。具体内容详见公司分别于 2025 年 1 月 22 日、2025 年 1 月 24 日披露于巨潮资讯网（www.cninfo.com.cn）等指定信息披露媒体的《关于回购公司股 份方案暨取得股票回购专项贷款的公告》（公告编号：2025-001）和《关于以集中竞价交 易方式回购公司股份的回购报告书》（公告编号：2025-005）。 根据《上市公司股份回购规则》《深圳证券交易 ...

Group 1 - The core viewpoint of the news is that Aomei Medical has shown a mixed performance in its stock price and financial results, with a slight increase in stock price recently but a decline over the past few trading days [1][2]. - As of January 5, Aomei Medical's stock price increased by 2.01% to 11.14 CNY per share, with a market capitalization of 7.055 billion CNY [1]. - The company reported a revenue of 2.597 billion CNY for the first nine months of 2025, representing a year-on-year growth of 5.98%, and a net profit of 349 million CNY, which is a 31.54% increase compared to the previous year [2]. Group 2 - Aomei Medical's main business involves the research, production, and sales of disposable medical consumables, with the revenue composition being 79.19% from surgical and wound care, 6.62% from other categories, 5.05% from infection protection, 4.68% from advanced dressings, and 4.46% from hygiene care [1]. - The company has distributed a total of 1.099 billion CNY in dividends since its A-share listing, with 91.913 million CNY distributed over the past three years [3]. - As of September 30, 2025, the number of shareholders increased to 37,800, with an average of 11,965 circulating shares per person, a decrease of 0.71% [2][3].

Group 1 - The company has completed the registration of changes in business and the amendment of its articles of association, following the resolutions passed in the board meeting and the shareholders' meeting held on October 24 and November 11, 2025 [1][3] - The company elected Mr. Li Yunsen as the employee representative director for the fourth board of directors, with the term starting from the approval date of the employee representative meeting until the end of the fourth board's term [1] - The company has received the registration notice from the Yichang Market Supervision Administration, confirming the completion of the business registration and the filing of the amended articles of association [3] Group 2 - The amended articles of association are available for review on the designated information disclosure media, including the official website [2][3] - The company ensures that the information disclosed is true, accurate, and complete, with no false records or misleading statements [1]

Core Viewpoint - Aomei Medical announced the convening of its third board meeting and the first extraordinary shareholders' meeting in November 2025 to review and approve various proposals related to the revision of company regulations and the election of board members [2] Group 1 - The company will hold the third board meeting on October 24, 2025, and the first extraordinary shareholders' meeting on November 11, 2025 [2] - The agenda includes the review of the company's revised regulations and the election of non-independent and independent directors for the fourth board [2] - The company has completed the board member election and the revision of the Articles of Association in accordance with relevant laws and regulations [2] Group 2 - On November 7, 2025, the company held a workers' representative meeting, where Mr. Li Yunsen was elected as the employee representative director for the fourth board [2] - The term of the newly elected director will last until the end of the fourth board's term [2] - The company has received the registration notice from the Yichang Market Supervision Administration, completing the business registration and the filing of the Articles of Association [2]